+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Siponimod"

From
Multiple Sclerosis Treatment Global Market Report 2025 - Product Thumbnail Image

Multiple Sclerosis Treatment Global Market Report 2025

  • Report
  • July 2025
  • 175 Pages
  • Global
From
Multiple Sclerosis Drugs Market Report 2025 - Product Thumbnail Image

Multiple Sclerosis Drugs Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
From
Multiple Sclerosis: Dynamic Market Forecast to 2026 - Product Thumbnail Image

Multiple Sclerosis: Dynamic Market Forecast to 2026

  • Report
  • November 2018
  • 53 Pages
  • Global
From
Neuroprotection - Methods, Drugs, Markets and Companies - Product Thumbnail Image

Neuroprotection - Methods, Drugs, Markets and Companies

  • Report
  • November 2021
  • 844 Pages
  • Global
From
  • 9 Results (Page 1 of 1)
Loading Indicator

Siponimod is a drug used to treat multiple sclerosis (MS). It is a sphingosine-1-phosphate receptor modulator, which works by blocking the action of certain immune cells that are involved in the development of MS. It is used to reduce the frequency of relapses and slow the progression of disability in people with relapsing forms of MS. It is also used to treat secondary progressive MS in adults. Siponimod is part of a larger class of drugs known as Central Nervous System (CNS) drugs. These drugs are used to treat a variety of neurological conditions, including MS, Alzheimer's disease, Parkinson's disease, and epilepsy. CNS drugs are typically prescribed by neurologists and other healthcare professionals. The market for Siponimod is highly competitive, with several companies offering the drug. These include Novartis, Biogen, Merck, and Teva Pharmaceuticals. Each company has its own unique formulation of the drug, which may vary in terms of efficacy and side effects. Show Less Read more